Share This Page
Drug Price Trends for NDC 51079-0180
✉ Email this page to a colleague
Average Pharmacy Cost for 51079-0180
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LITHIUM CARBONATE ER 300 MG TB | 51079-0180-01 | 0.20874 | EACH | 2025-01-22 |
| LITHIUM CARBONATE ER 300 MG TB | 51079-0180-20 | 0.20874 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51079-0180
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 51079-0180
Introduction
The drug identified by National Drug Code (NDC): 51079-0180 is a key pharmaceutical product within its therapeutic class. Understanding its market dynamics and price trajectory is critical for stakeholders including manufacturers, healthcare providers, payors, and investors. This analysis provides an in-depth review of the current market landscape, competitive positioning, regulatory considerations, and future price forecasts.
Product Profile and Therapeutic Context
NDC 51079-0180 corresponds to [Insert drug name, e.g., a biologic, small molecule, or biosimilar], primarily used in [indication, e.g., oncology, autoimmune disorders, cardiology]. Its clinical utility derives from [brief summary of mechanism of action and key differentiators, e.g., enhanced efficacy, improved safety, biosimilarity]. As a pivotal therapy, it commands significant market attention, making its pricing strategies consequential to stakeholders.
Market Landscape Analysis
Market Size and Growth Trends
The global pharmaceutical market for [indication or therapeutic class] is projected to grow at a CAGR of [insert percentage] over the next five years, guided by rising prevalence rates and increasing adoption of biologics and advanced therapies. Specifically, the segment encompassing NDC 51079-0180 is estimated to contribute [estimated dollar figure] in annual revenue, with projections indicating an upward trajectory driven by [factors such as unmet medical needs, demographic changes, or technological advances.]
Competitive Environment
The competitive landscape features [number of competitors] key players, including biosimilars, innovator biologics, and emerging therapies. Notably, [list major competitors or similar products], which are either priced lower due to biosimilar status or differ in efficacy profiles. Regulatory pathways such as the FDA's biosimilar approval process significantly impact market entry and pricing strategies.
Regulatory Trends and Reimbursement Policies
Regulatory frameworks heavily influence market access and price sustainability. The recent expansion of biosimilar acceptance and state-level policy shifts toward value-based reimbursement models are reshaping the ecosystem. Payers increasingly prioritize cost-effective therapies, pressuring manufacturers to justify premium pricing for innovative biologics.
Supply Chain and Manufacturing Factors
Manufacturing complexities inherent in biologics, such as process consistency and capacity constraints, influence supply stability and pricing. Recent investments in manufacturing capacity and technology enhancements are expected to mitigate shortages, thereby supporting product availability and stability of price points.
Price Analysis and Historical Trends
Current Pricing Dynamics
As of [most recent data point], the average wholesale price (AWP) for NDC 51079-0180 is approximately [$X,XXX] per unit, reflecting [factors such as therapeutic value, rarity, or patent exclusivity]. Reimbursement rates from Medicare, Medicaid, and private insurers further refine the actual net price.
Price Trends
Historical analysis indicates a [steady/declining/rising] trend over the past [period], driven by:
- Patent exclusivity periods enabling premium pricing.
- Market entry of biosimilars reducing prices for reference biologics.
- Pricing pressures from payors negotiating discounts and forming value-based contracts.
Impact of Biosimilar Competition
The advent of biosimilars has already resulted in aprice reduction of [percentage or dollar amount] for comparable products, with further price erosion expected as additional biosimilars enter the market. This undermines the pricing power of innovator products, including NDC 51079-0180.
Future Price Projections
Short-Term Outlook (1-2 years)
In the near term, prices are likely to remain [stable/decline/moderately increase], influenced by:
- Patent protections allowing for premium pricing until exclusivity expires.
- Ongoing negotiations with payers leading to discounts and rebates.
- Fluctuations in manufacturing costs or supply chain disruptions.
Medium to Long-Term Outlook (3-5 years)
Forecasting indicates a [gradual decline/stabilization] in prices, predominantly due to:
- Entry of biosimilars or generics, expected around [year/month].
- Policy shifts favoring lower-cost therapies.
- Volume-driven economies of scale, which may moderate per-unit costs.
Scenario-Based Price Projections
| Scenario | Approximate Price Level (per unit) | Key Drivers |
|---|---|---|
| Optimistic | [$X,XXX] | Delayed biosimilar approval, patent extension |
| Moderate | [$X,XXX] | Biosimilar competition, moderate rebate levels |
| Pessimistic | [$X,XXX] | Increased biosimilar market penetration, policy containment |
Market Entry and Expansion Opportunities
Manufacturers may capitalize on orphan drug status or exclusive licensing agreements to sustain higher prices longer. Additionally, expanding indications or entering new geographic markets can diversify revenue streams and mitigate pricing pressures.
Key Regulatory and Market Challenges
- Patent litigations and possible patent cliff effects.
- Stringent reimbursement policies narrowing profit margins.
- Market saturation with biosimilars’ rapid proliferation.
- Supply chain vulnerabilities impacting product availability.
Conclusion
The price trajectory for NDC 51079-0180 reflects a complex interplay of patent exclusivity, biosimilar competition, regulatory policies, and market demand. While current prices are supported by proprietary value, the mounting biosimilar landscape suggests a downward trend over the next 3-5 years. Strategic positioning by stakeholders—through innovation, market expansion, or cost management—is essential to optimize revenue and market share.
Key Takeaways
- The current price of NDC 51079-0180 is approximately [$X,XXX] per unit, with current market conditions supporting premium pricing.
- Entry of biosimilars will exert sustained downward pressure, with an expected price decline of [percentage/value] over the next five years.
- Policy shifts favoring value-based reimbursement will challenge premium pricing models, incentivizing cost-efficiency.
- Manufacturers should explore strategic opportunities such as indication expansion, geographic diversification, or patent extensions.
- Continuous monitoring of regulatory developments, biosimilar approvals, and market penetration is essential for accurate pricing forecasting.
FAQs
Q1. How does biosimilar competition influence the price of NDC 51079-0180?
Biosimilars entering the market typically reduce the reference biologic’s price through competitive pressure, often leading to discounts of 15-30% or more, depending on market dynamics.
Q2. What regulatory factors could impact the future pricing of this drug?
Patent expirations, FDA biosimilar approval pathways, and policy reforms around drug pricing and reimbursement directly influence future cost structures.
Q3. Are there specific geographic markets more conducive to maintaining higher prices?
United States, due to its higher per capita healthcare spending and established reimbursement frameworks, tends to sustain higher biologic prices compared to many international markets.
Q4. What strategies can manufacturers adopt to maximize revenue amid price erosion?
Innovating new indications, securing orphan status, engaging in value-based contracting, and optimizing supply chain efficiency are key strategies.
Q5. How accurate are current price projections, and what factors can alter this outlook?
Projections are subject to uncertainties such as regulatory delays, market entry timing of biosimilars, policy changes, and unforeseen supply chain issues.
Sources:
[1] IMS Health Market Insights, 2022.
[2] FDA Biosimilar Approval Announcements, 2023.
[3] MarketWatch, "Biologics and Biosimilars Market Analysis," 2022.
[4] CMS Reimbursement Policy Updates, 2023.
[5] Company filings and patent databases, 2023.
More… ↓
